검색어 : 통합검색[Anderson Denise G..]
총 146건 중 146건 출력
, 13/15 페이지
-
121
- Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.
- Burgess, Melissa Amber; Bolejack, Vanessa; Schuetze, Scott; Van Tine, Brian Andrew; Attia, Steven; Riedel, Richard F.; Hu, James S; Davis, Lara Emily; Okuno, Scott H.; Priebat, Dennis A.; Movva, Sujana; Reed, Damon R.; D'Angelo, Sandra P.; Lazar, Alexander J.; Keung, Emily Zhi-Yun; Reinke, Denise K.; Baker, Laurence H.; Maki, Robert G.; Patel, Shreyaskumar; Tawbi, Hussein Abdul-Hassan; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA; ; Cancer Research and Biostatistics, Seattle, WA; ; University of Michigan, Ann Arbor, MI; ; Washington University in St. Louis, St. Louis, MO; ; Mayo Clinic, Jacksonville, FL; ; Duke University Medical Center, Durham, NC; ; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; ; Oregon Health & Science University, Portland, OR; ; Mayo Clinic, Rochester, MN; ; Washington Hospital Center, Washington, DC; ; Fox Chase Cancer Center, Philadelphia, PA; ; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; ; Memorial Sloan-Kettering Cancer Center, New York, NY; ; The University of Texas MD Anderson Cancer Center, Houston, TX; ; Brigham and Womens Hosp, Brookline, MA; ; SARC, Ann Arbor, MI; ; University of Michigan, Ann Arbor, MI; ; Northwell Cancer Institute and Cold Spring Harbor Laboratory, New Hyde Park, NY; ; The University of Texas MD Anderson Cancer Center, Houston,; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.37, 2019, pp.11015-11015)
-
122
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
- Maki, Robert G.; Wathen, J. Kyle; Patel, Shreyaskumar R.; Priebat, Dennis A.; Okuno, Scott H.; Samuels, Brian; Fanucchi, Michael; Harmon, David C.; Schuetze, Scott M.; Reinke, Denise; Thall, Peter F.; Benjamin, Robert S.; Baker, Laurence H.; Hensley, Martee L.; From the Department of Medicine, Memorial Sloan-Kettering Cancer Center New York, NY; Department of Biostatistics & Applied Mathematics and Sarcoma Center, Department of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Washington Cancer Institute, Section of Hematology/Oncology, Washington, DC; Mayo Clinic, Rochester, MN; University of Illinois at Chicago, Oncology Specialists, Park Ridge, IL; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; Partners'...; From the Department of Medicine, Memorial Sloan-Kettering Cancer Center New York, NY; Department of Biostatistics & Applied Mathematics and Sarcoma Center, Department of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Washington Cancer Institute, Section of Hematology/Oncology, Washington, DC; Mayo Clinic, Rochester, MN; University of Illinois at Chicago, Oncology Specialists, Park Ridge, IL; Winship Cancer Institute, Emory University School of Medicine; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.25, 2007, pp.2755-2763)
-
123
- Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.
- Burgess, Melissa Amber; Bolejack, Vanessa; Van Tine, Brian Andrew; Schuetze, Scott; Hu, James; D'Angelo, Sandra P.; Attia, Steven; Priebat, Dennis A.; Okuno, Scott H.; Riedel, Richard F.; Davis, Lara Emily; Movva, Sujana; Reed, Damon R.; Butterfield, Lisa Helene; Roszik, Jason; Reinke, Denise K.; Baker, Laurence H.; Maki, Robert G.; Patel, Shreyaskumar; Tawbi, Hussein Abdul-Hassan; University of Pittsburgh Physicians, Pittsburgh, PA; ; Cancer Research and Biostatistics, Seattle, WA; ; Washington University in St. Louis, St. Louis, MO; ; University of Michigan, Ann Arbor, MI; ; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; ; Mayo Clinic, Jacksonville, FL; ; Washington Hospital Center, Washington, DC; ; Mayo Clinic, Rochester, MN; ; Duke University Medical Center, Durham, NC; ; Oregon Health & Science University, Portland, OR; ; Fox Chase Cancer Center, Philadelphia, PA; ; Moffitt Cancer Center, Tampa, FL; ; University of Pittsburgh Cancer Institute/Hillman Cancer Center, Pittsburgh, PA; ; The University of Texas MD Anderson Cancer Center, Houston, TX; ; SARC, Ann Arbor, MI; ; University of Michigan, Ann Arbor, MI; ; Monter Cancer Center, Northwell Health and Cold Spring Harbor Laboratory, Lake Success, NY; ; The University of Texas MD Anderson C; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.35, 2017, pp.11008-11008)
-
124
- S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
- Brown, Jennifer R.; Desikan, Sai Prasad; Nguyen, Bastien; Won, Helen; Tantawy, Shady; Mcneely, Samuel Clark; Marella, Narasimha; Ebata, Kevin; Woyach, Jennifer; Patel, Krish; Tam, Constantine; Eyre, Toby; Cheah, Chan; Shah, Nirav N; Ghia, Paolo; Jurczak, Wojciech; Balbas, Minna; Nair, Binoj; Abada, Paolo; Wang, Chunxiao; Wang, Denise; Mato, Anthony R.; Gandhi, Varsha; Wierda, William G.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States; University of Texas MD Anderson Cancer Center, Houston, United States; Loxo@Lilly, Indianapolis, United States; Loxo@Lilly, Indianapolis, United States; University of Texas MD Anderson Cancer Center, Houston, United States; Eli Lilly and Company, Indianapolis, United States; Loxo@Lilly, Indianapolis, United States; Loxo@Lilly, Indianapolis, United States; The Ohio State University Comprehensive Cancer Center, Columbus, United States; Swedish Cancer Institute, Seattle, United States, Center for Blood Disorders and Cellular Therapy, Seattle, United States; Alfred Health and Monash University, Melbourne, Australia; Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; Medical College of Wisconsin, Milwaukee, United States; Università Vita-Salute San Raffaele and IRCCS; (Hemasphere : Open access journal of the european hematology association, v.7, 2023, pp.e6233246)
-
125
- HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).
- Miller, Kathy; Cortes, Javier; Hurvitz, Sara A.; Krop, Ian E.; Tripathy, Debu; Verma, Sunil; Dionne, Michelle; Campbell, Karen; Reynolds, Joseph G.; Wickham, Thomas J.; Molnar, Istvan; Yardley, Denise A.; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; ; Vall d'Hebron Institute of Oncology, Barcelona, Spain; ; UCLA Healthcare Hematology-Oncology Breast Oncology Program, Santa Monica, CA; ; Dana-Farber Cancer Institute, Boston, MA; ; The University of Texas MD Anderson Cancer Center, Houston, TX; ; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; ; Merrimack, Cambridge, MA; ; Merrimack Pharmaceuticals, Cambridge, MA; ; Merrimack Pharmaceuticals, Inc., Cambridge, MA; ; Merrimack Pharmaceuticals, Inc., Cambridge, MA; ; Merrimack Pharmaceuticals, Inc., Cambridege, MA; ; Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.34, 2016, pp.TPS631-TPS631)
-
126
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- Hoadley, Katherine A.; Yau, Christina; Hinoue, Toshinori; Wolf, Denise M.; Lazar, Alexander J.; Drill, Esther; Shen, Ronglai; Taylor, Alison M.; Cherniack, Andrew D.; Thorsson, Vé steinn; Akbani, Rehan; Bowlby, Reanne; Wong, Christopher K.; Wiznerowicz, Maciej; Sanchez-Vega, Francisco; Robertson, A. Gordon; Schneider, Barbara G.; Lawrence, Michael S.; Noushmehr, Houtan; Malta, Tathiane M.; Stuart, Joshua M.; Benz, Christopher C.; Laird, Peter W.; Department of Genetics, Lineberger Comprehensive Cancer Center, the University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Buck Institute for Research on Aging, Novato, CA 94945, USA; Van Andel Research Institute, Grand Rapids, MI 49503, USA; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94115, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Institute for Systems Biology, Seattle, WA 98109, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson; (Cell, v.173, 2018, pp.291-304.e6)
-
127
- Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.
- Hecht, J. Randolph Randolph; Kopetz, Scott; Patel, Sandip Pravin; Welling, Theodore; Morelli, Maria Pia; Borad, Mitesh J.; Molina, Julian R.; Kirtane, Kedar; Lin, Yi; Fan-Port, Michelle; Mardiros, Armen; Beutner, Karl; Lozac'hmeur, Ariane; Lau, Denise; Liechty, Kirstin B.; Vong, Judy; Ng, Eric; Maloney, David G.; Go, William Y.; Simeone, Diane M.; David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA; ; The University of Texas MD Anderson Cancer Center, Houston, TX; ; Department of Medical Oncology, University of California San Diego, San Diego, CA; ; Department of Surgery, New York University Langone Health, New York, NY; ; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; ; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ; ; Division of Medical Oncology, Mayo Clinic, Rochester, MN; ; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL; ; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN; ; A2 Biotherapeutics, Inc., Agoura Hills, CA; ; A2 Biotherapeutics, Inc., Agoura Hills, CA; ; Tempus, Chicago, IL; ; Tempus, Chicago, IL; ; Tempus, Chicago, IL; ; A2 Biotherapeutics, Inc., Agoura Hills, CA; ; A2 Biotherap; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.40, 2022, pp.190-190)
-
128
- Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase
- Yang, Ju Dong; Dai, Jianliang; Singal, Amit G.; Gopal, Purva; Addissie, Benyam D.; Nguyen, Mindie H.; Befeler, Alex S.; Reddy, K. Rajender; Schwartz, Myron; Harnois, Denise M.; Yamada, Hiroyuki; Gores, Gregory J.; Feng, Ziding; Marrero, Jorge A.; Roberts, Lewis R.; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.; Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas.; Division of Digestive and Liver Disease, UT Southwestern Medical Center, Dallas, Texas.; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.; Division of Gastroenterology, Stanford University Medical Center, Palo Alto, California.; Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, Missouri.; Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.; Department of General Surgery, The Mount Sinai Medical Center, New York, New York.; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Jacksonville, Florida.; Wako Diagnostics, Mountain View, Californi; (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, v.26, 2017, pp.1085-1092)
-
129
- A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small-cell lung cancer (NSCLC).
- Paz-Ares, Luis G.; Gay, Carl Michael; Zhou, Caicun; Kato, Terufumi; Corrales, Luis; Redhead, Karl; Rahman, Ahmadur; Bradley, Denise; Theogaraj, Elizabeth; Hutchinson, Katherine E.; Shagan, Sarah M.; Solomon, Benjamin J.; Hospital Universitario, 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain; Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, China; Kanagawa Cancer Center, Yokohama, Japan; Centro de Investigació n y Manejo del Cá ncer (CIMCA), San José , Costa Rica; Roche Products Ltd, Welwyn Garden City, United Kingdom; Roche Products Ltd, Welwyn Garden City, United Kingdom; Roche Products Ltd, Welwyn Garden City, United Kingdom; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Genentech, Inc., South San Francisco, CA; Genentech, Inc., South San Francisco, CA; Peter MacCallum Cancer Centre, Melbourne, Australia; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.41, 2023, pp.TPS8605-TPS8605)
-
130
- Associations between hippocampal morphometry and neuropathologic markers of Alzheimer's disease using 7T MRI
- Blanken, Anna E.; Hurtz, Sona; Zarow, Chris; Biado, Kristina; Honarpisheh, Hedieh; Somme, Johanne; Brook, Jenny; Tung, Spencer; Kraft, Emily; Lo, Darrick; Ng, Denise W.; Vinters, Harry V.; Apostolova, Liana G.; Department of Psychology, University of Southern California; Drexel University College of Medicine; Department of Neurology, Keck School of Medicine at the University of Southern California; Department of Pathology & Laboratory Medicine, UCLA; Department of Pathology, University of Texas MD Anderson Cancer Center; Department of Neurology; Department of Medicine - Statistics Core, UCLA; Department of Pathology & Laboratory Medicine, UCLA; University of Rochester; Department of Pathology & Laboratory Medicine, UCLA; Department of Pathology & Laboratory Medicine, UCLA; Department of Pathology & Laboratory Medicine, UCLA; Department of Neurology, David Geffen School of Medicine, University of California L; (NeuroImage : Clinical, v.15, 2017, pp.56-61)
QUICK MENU
